Literature DB >> 25001277

Quality of life in a cohort of high-dose benzodiazepine dependent patients.

Fabio Lugoboni1, Antonio Mirijello2, Marco Faccini1, Rebecca Casari1, Anthony Cossari3, Gessica Musi1, Giorgia Bissoli1, Gianluca Quaglio1, Giovanni Addolorato4.   

Abstract

BACKGROUND: Benzodiazepines (BZD) are among the most widely prescribed drugs in developed countries. Since BZD can produce tolerance and dependence even in a short time, their use is recommended for a very limited time. However, these recommendations have been largely disregarded. The chronic use of BZD causes a number of serious side effects, i.e., cognitive impairment, falls, traffic accidents, dependence and tolerance. The aim of the present study was to evaluate quality of life (QoL) in a cohort of 62 consecutive high-dose BZD-dependent patients seeking a BZD detoxification.
METHODS: Patients seeking BZD detoxification were evaluated using the General Health Questionnaire (GHQ-12) and the short form-36 questionnaire (SF-36).
RESULTS: Patients showed a significant reduction of QoL as measured by either SF-36 or GHQ-12. In particular, the greater impairment was observed in the items exploring physical and emotional status. Physical functioning was the item more influenced by the length of BZD abuse. Female patients showed a greater reduction of QoL compared to male, at least in some of the explored items. Social functioning scores were greatly reduced.
CONCLUSIONS: The present study shows for the first time that high-doses BZD dependent patients have a reduced QoL and a reduced social functioning, along with high levels of psychological distress.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  BZD; Benzodiazepines; Dependence; GHQ12; Megadose; QoL; SF36; Tolerance

Mesh:

Substances:

Year:  2014        PMID: 25001277     DOI: 10.1016/j.drugalcdep.2014.06.020

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  20 in total

Review 1.  Identification and management of alcohol withdrawal syndrome.

Authors:  Antonio Mirijello; Cristina D'Angelo; Anna Ferrulli; Gabriele Vassallo; Mariangela Antonelli; Fabio Caputo; Lorenzo Leggio; Antonio Gasbarrini; Giovanni Addolorato
Journal:  Drugs       Date:  2015-03       Impact factor: 9.546

2.  Multifocal cognitive dysfunction in high-dose benzodiazepine users: a cross-sectional study.

Authors:  Angela Federico; Stefano Tamburin; Alice Maier; Marco Faccini; Rebecca Casari; Laura Morbioli; Fabio Lugoboni
Journal:  Neurol Sci       Date:  2016-10-11       Impact factor: 3.307

3.  The epidemiology of benzodiazepine misuse: A systematic review.

Authors:  Victoria R Votaw; Rachel Geyer; Maya M Rieselbach; R Kathryn McHugh
Journal:  Drug Alcohol Depend       Date:  2019-05-07       Impact factor: 4.492

4.  Work-Related Stressors and Increased Risk of Benzodiazepine Long-Term Use: Findings From the CONSTANCES Population-Based Cohort.

Authors:  Guillaume Airagnes; Cédric Lemogne; Romain Olekhnovitch; Yves Roquelaure; Nicolas Hoertel; Marcel Goldberg; Frédéric Limosin; Marie Zins
Journal:  Am J Public Health       Date:  2018-11-29       Impact factor: 9.308

5.  The role of dual diagnosis in health-related quality of life among treatment-seeking patients in Spain.

Authors:  Constanza Daigre; Lara Grau-López; Laia Rodríguez-Cintas; Elena Ros-Cucurull; Marta Sorribes-Puertas; Oriol Esculies; Katia Bones-Rocha; Carlos Roncero
Journal:  Qual Life Res       Date:  2017-08-07       Impact factor: 4.147

6.  Diazepam filled hard capsules intended for detoxification of patients addicted to benzodiazepines and Z-drugs.

Authors:  Aleš Franc; Kateřina Kubová; Jan Elbl; Jan Muselík; David Vetchý; Jan Šaloun; Radka Opatřilová
Journal:  Eur J Hosp Pharm       Date:  2017-07-24

Review 7.  Efficacy and safety of Z-substances in the management of insomnia in older adults: a systematic review for the development of recommendations to reduce potentially inappropriate prescribing.

Authors:  Vincenz Scharner; Lukas Hasieber; Andreas Sönnichsen; Eva Mann
Journal:  BMC Geriatr       Date:  2022-02-01       Impact factor: 3.921

8.  Determinants of Quality of Life in High-Dose Benzodiazepine Misusers.

Authors:  Stefano Tamburin; Angela Federico; Marco Faccini; Rebecca Casari; Laura Morbioli; Valentina Sartore; Antonio Mirijello; Giovanni Addolorato; Fabio Lugoboni
Journal:  Int J Environ Res Public Health       Date:  2017-01-04       Impact factor: 3.390

9.  Perceived quality of life, 6 months after detoxification: Is abstinence a modifying factor?

Authors:  John-Kåre Vederhus; Bente Birkeland; Thomas Clausen
Journal:  Qual Life Res       Date:  2016-03-19       Impact factor: 4.147

10.  Quality of Life in Patients with Substance Use Disorders Admitted to Detoxification Compared with Those Admitted to Hospitals for Medical Disorders: Follow-Up Results.

Authors:  John-Kåre Vederhus; Are Hugo Pripp; Thomas Clausen
Journal:  Subst Abuse       Date:  2016-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.